Peer Review History

Original SubmissionSeptember 14, 2023
Decision Letter - Valérie Pittet, Editor

PONE-D-23-29768Quality Improvement Exercises in Inflammatory Bowel Disease (IBD) Services: A Scoping ReviewPLOS ONE

Dear Dr. Ridsdale,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please submit your revised manuscript by Jan 29 2024 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.
  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.
  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Valérie Pittet, PhD

Academic Editor

PLOS ONE

Journal requirements:

1. When submitting your revision, we need you to address these additional requirements.

Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at 

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and 

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf.

2. Note from Emily Chenette, Editor in Chief of PLOS ONE, and Iain Hrynaszkiewicz, Director of Open Research Solutions at PLOS: Did you know that depositing data in a repository is associated with up to a 25% citation advantage (https://doi.org/10.1371/journal.pone.0230416)? If you’ve not already done so, consider depositing your raw data in a repository to ensure your work is read, appreciated and cited by the largest possible audience. You’ll also earn an Accessible Data icon on your published paper if you deposit your data in any participating repository (https://plos.org/open-science/open-data/#accessible-data).

3. Thank you for stating the following in the Competing Interests section: 

[I have read the journal's policy and the authors of this manuscript have the following competing interests: Professor Alan Lobo has acted as a consultant and advisory board member for Takeda Pharma, Janssen and Bristol Myers Squibb.]. 

Please confirm that this does not alter your adherence to all PLOS ONE policies on sharing data and materials, by including the following statement: ""This does not alter our adherence to  PLOS ONE policies on sharing data and materials.” (as detailed online in our guide for authors http://journals.plos.org/plosone/s/competing-interests).  If there are restrictions on sharing of data and/or materials, please state these. Please note that we cannot proceed with consideration of your article until this information has been declared. 

Please include your updated Competing Interests statement in your cover letter; we will change the online submission form on your behalf.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: N/A

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: The authors present a very thorough scoping review of published quality improvement interventions in IBD. This expands on a prior work to include pediatric studies and non-American studies, as well as a broader variety of metrics. Bringing all of these studies together is an achievement and worthy of publication. However, the synthesis and "take home messages" from the review could be improved. Most notably, Table 2 needs significant improvement, and the outcomes of unsuccessful interventions need mention.

--The authors refer to the IBD standards, which presumably are the NHS standards. These are likely unfamiliar to most outside the UK. Consider reframing the categorizations to a set of topics that is more universally understood. Alternatively, though less ideally, these should be explained in adequate detail for a reader unfamiliar with the concept to understand their use in the paper.

-- Stratified care is referred to - could the authors clarify why the topics of anemia, PSC and obesity are grouped together under this?

-- The results describe successful interventions, but not those which reported a lack of success. Publication bias notwithstanding, it is worthwhile to understand what hasn't work (rather than just what has).

-- Table 2 is the most important piece of the work, however it is too vague to be helpful to readers looking to understand characteristics of successful interventions. Consider structuring the table such that each intervention category under each problem category has a row. This would allow the measures used to be reported in a new column, and a more detailed description of the intervention for each can be provided. Most crucially, it should be clear exactly what is being improved and how this was accomplished. This table should serve almost as a "standalone" such that a reader would understand much of the paper looking at just this table, though of course should be more digestible than S4

-- S4 should be expanded similarly so that it is clear what is being improved and how, rather than just general categories. The present version is helpful to narrow the selection of papers to look at if interested in a specific metric, but more summary is appropriate.

-- There is a potential missed opportunity in the discussion to translate the results into take home messages for clinicians looking to improve the quality of their center's care. Consider making thematic conclusions about what has worked -- either by type of metric or by type of intervention.

-- A limitation of the work is the search strategy, which may have missed works that were not captured by QI terms, but that were in fact QI studies targeting specific metrics. This is understandable and should be noted as a limitation.

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

**********

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

Revision 1

We would like to express our thanks to you and the reviewer for reviewing our manuscript. We appreciate the consideration of our paper, and the detailed response provided. The comments given were insightful, and by addressing these we believe that we have improved the quality of this report. Please see details on how we have addressed the reviewer comments below:

• Use of the IBD standards: The IBD standards are not NHS standards, but were developed by IBD UK. We believe these are useful for categorisation as they describe the stages of the patient journey, allowing us to highlight areas of the journey with fewer published quality improvement papers. However, we agree that the definition of these required more explanation, therefore have defined these in the introduction (page 3) and further expanded on this in the methods (pages 7 to 8).

• Grouping of anaemia, PSC and obesity in stratified care: PSC and obesity have been grouped here as these two papers focus on specific subsets of IBD patients – screening/treatment specific to those with additional conditions. However, after consideration, the anaemia article has been re-categorised into ‘Screening’ as this did focus on the whole population.

• Description of unsuccessful studies: As mentioned by the reviewer, due to publication biases, almost all articles report some level of success, leaving little insight into unsuccessful interventions. As we have now added results to Table 2 and S4, it should be clearer how successful the individual interventions were.

• Expansion of Table 2: We have added more details on the intervention components and the outcomes/results for all papers. Though we attempted to structure as suggested, with intervention categories in separate rows alongside outcomes, this looked very unclear, as individual articles used multiple interventions. However, by adding the details, and by adding an extra ‘overarching theme’ column, we believe this more clearly shows what is being improved and how it was accomplished, allowing the table to serve as a standalone if necessary.

• Expansion of S4: Similarly to table 2, we have added intervention components and outcomes to S4 to provide more summaries of the research.

• Translation of results into take-home messages: We have added overarching themes to Table 2, and added further thoughts to the discussion.

• Limitation of search strategy: We have added this the limitations section.

Finally, as requested, I have updated our statement regarding competing interests, as follows. Thank you for changing this in our online submission form: I have read the journal's policy and the authors of this manuscript have the following competing interests: Professor Alan Lobo has acted as a consultant and advisory board member for Takeda Pharma, Janssen and Bristol Myers Squibb. This does not alter our adherence to PLOS ONE policies on sharing data and materials.

Attachments
Attachment
Submitted filename: Response to Reviewers.docx
Decision Letter - Valérie Pittet, Editor

Quality Improvement Exercises in Inflammatory Bowel Disease (IBD) Services: A Scoping Review

PONE-D-23-29768R1

Dear Dr. Ridsdale,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Valérie Pittet, PhD

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #1: All comments have been addressed

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: N/A

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: I thank the authors for their extensive efforts at improving the manuscript, particularly because their improvements will make their work much more approachable for teams looking for QI approaches for the IBD population under their care.

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

**********

Formally Accepted
Acceptance Letter - Valérie Pittet, Editor

PONE-D-23-29768R1

PLOS ONE

Dear Dr. Ridsdale,

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now being handed over to our production team.

At this stage, our production department will prepare your paper for publication. This includes ensuring the following:

* All references, tables, and figures are properly cited

* All relevant supporting information is included in the manuscript submission,

* There are no issues that prevent the paper from being properly typeset

If revisions are needed, the production department will contact you directly to resolve them. If no revisions are needed, you will receive an email when the publication date has been set. At this time, we do not offer pre-publication proofs to authors during production of the accepted work. Please keep in mind that we are working through a large volume of accepted articles, so please give us a few weeks to review your paper and let you know the next and final steps.

Lastly, if your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

If we can help with anything else, please email us at customercare@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

PD Dr. Valérie Pittet

Academic Editor

PLOS ONE

Open letter on the publication of peer review reports

PLOS recognizes the benefits of transparency in the peer review process. Therefore, we enable the publication of all of the content of peer review and author responses alongside final, published articles. Reviewers remain anonymous, unless they choose to reveal their names.

We encourage other journals to join us in this initiative. We hope that our action inspires the community, including researchers, research funders, and research institutions, to recognize the benefits of published peer review reports for all parts of the research system.

Learn more at ASAPbio .